A randomized phase III study of cisplatin with or without methotrexate for recurrent squamous cell carcinoma of the head and neck. A northern California oncology group study

C. Jacobs, Frederick J Meyers, C. Hendrickson, M. Kohler, S. Carter

Research output: Contribution to journalArticle

48 Scopus citations


Eighty patients with recurrent squamous cell cancer of the head and neck were randomized to cisplatin (80 mg/m2) every 3 weeks or cisplatin plus weekly methotrexate (250 mg/m2) with leucovorin. The overall response rate to cisplatin was 18%, with 10% complete responses. The overall response to the combination was 33% with 18% complete responses (P - 0.11). There was no difference in response duration, time to progression, or survival. There was no difference in renal toxicity between the 2 arms (creatinine > 2 mg/dl in 6% of the patients). There was significantly more leukopenia (64%), thrombocytopenia (18%), anemia (18%), and mucositis (33%) in the combination arm. This combination of two of the best agents for head and neck cancer did not improve response, but resulted in added toxicity.

Original languageEnglish (US)
Pages (from-to)1563-1569
Number of pages7
Issue number9
StatePublished - 1983
Externally publishedYes


ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this